Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $16.78M
• Dividend Yield: N/A
• Average Volume (3M): 1.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: N/A
• EPS Growth: 18.73%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 22,376,427
• 10 Day Avg. Volume: 511,305
• 30 Day Avg. Volume: 1,160,981
• PEG Ratio: <0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: 0.37
• Enterprise Value/Gross Profit: 0.61
• Enterprise Value/Ebitda: -0.04
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.9
• Revenue Forecast (FY): $63.82M

• Rating: 45 Neutral
• Price Target: $0.70 ▼(-18.72% Downside)
• Action: Reiterated Date: 02/19/26
• Date: Action: Reiterated 02/19/26

The score is driven primarily by weak financial performance (large ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). A low-debt balance sheet provides some support, and the LYMPHIR launch is a notable positive catalyst, but current profitability and funding dependence keep the overall score low.

Positive Factors

Commercial Launch (LYMPHIR)

FDA approval and a commercial launch move Citius from pure development into commercialization. LYMPHIR establishes a sales channel, distributor relationships and go-to-market capability that can generate durable revenue, support scaling, and enable international and investigator-initiated expansion.

Initial Product Revenue

Recording initial revenue validates early physician uptake and commercial execution, de-risking the business model incrementally. Sustainable repeat sales could underpin organic growth, reduce sole reliance on equity raises, and provide funding support for additional trials or market expansion.

Low Leverage / Equity Base

Very low debt and a sizable equity base provide structural financial flexibility versus peers. Limited leverage reduces insolvency risk and preserves options to fund commercialization, pursue partnerships, or absorb delays, supporting operations over the next several months while revenue ramps.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow (~-$34.8M TTM) creates an enduring funding gap that forces reliance on external capital or milestone receipts. Over months this increases dilution risk or the need for non-dilutive deals, constraining strategic flexibility during commercialization.

Ongoing Losses & Negative ROE

Large trailing operating losses and a roughly -54% ROE indicate persistent unprofitability and shareholder value erosion. Structurally, this undermines internal funding capacity, heightens dependency on external financing, and raises execution risk for scaling commercial operations over the coming months.

Nasdaq Listing Compliance Risk

A formal Nasdaq notice for minimum bid-price noncompliance creates a tangible near-term structural risk. Potential delisting or corrective actions (e.g., reverse split) would impair capital access, increase financing costs, and distract management from executing the LYMPHIR launch during a critical growth window.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

How the Company Makes Money

Citius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary

Overall financials are weak due to large, persistent losses and cash burn (TTM EBIT about -$37.5M; TTM operating/free cash flow about -$34.8M). The main offset is a relatively strong balance sheet with minimal leverage (debt-to-equity ~0.01) and sizable equity (~$80.0M), but negative ROE (~-54% TTM) highlights ongoing dilution and funding risk.

Income Statement

CTXR remains firmly loss-making. In TTM (Trailing-Twelve-Months), the company generated ~$3.9M of revenue with strong gross profitability (~76% gross margin), but operating costs are far larger than revenue, driving a very large operating loss (EBIT of about -$37.5M) and net loss (about -$37.1M), implying deeply negative profitability. Annual periods from 2021–2025 show little to no recurring revenue, and losses have not shown a sustained improving trajectory, which keeps overall earnings quality and visibility weak.

Balance Sheet

The balance sheet is a relative strength. Leverage is very low (TTM debt-to-equity ~0.01), and equity remains sizable (~$80.0M TTM), providing financial flexibility versus many early-stage biotech peers. However, negative returns on equity (around -54% TTM) reflect continued losses and ongoing value dilution risk if the company needs additional capital to fund operations.

Cash Flow

Cash generation is weak with persistent cash burn. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow were both about -$34.8M, and the business is not self-funding. While the cash burn rate has fluctuated year to year (with some periods showing improvement and others worsening), the overall pattern remains consistently negative, increasing dependence on financing or successful commercialization milestones.

Breakdown	TTM	Sep 2025	Sep 2024	Dec 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	3.94M	0.00	0.00	0.00	0.00	0.00
Gross Profit	2.42M	-214.25K	-209.61K	-194.32K	-179.68K	-164.87K
EBITDA	-36.68M	-38.20M	-38.64M	-31.77M	-32.88M	-22.88M
Net Income	-35.89M	-37.43M	-39.14M	-32.54M	-33.64M	-23.13M
Balance Sheet
Total Assets	140.39M	130.94M	116.65M	103.61M	114.00M	142.43M
Cash, Cash Equivalents and Short-Term Investments	7.72M	4.25M	3.25M	26.48M	41.71M	70.07M
Total Debt	829.65K	1.81M	262.87K	481.25K	678.23K	855.47K
Total Liabilities	46.92M	53.41M	42.55M	12.18M	10.57M	9.65M
Stockholders Equity	79.96M	67.55M	70.08M	90.83M	102.83M	132.18M
Cash Flow
Free Cash Flow	-34.84M	-26.55M	-28.20M	-29.06M	-28.36M	-64.26M
Operating Cash Flow	-34.84M	-26.55M	-28.20M	-29.06M	-28.36M	-24.25M
Investing Cash Flow	-10.15M	-5.75M	-5.00M	0.00	0.00	-40.01M
Financing Cash Flow	51.61M	33.30M	9.97M	13.83M	0.00	120.47M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.86
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Negative. The current price of 0.86 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.85, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.33 is Neutral, neither overbought nor oversold. The STOCH value of 23.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRKR	53 Neutral	$27.18M	―	-110.67%	―	-12.99%	-13.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PASG	49 Neutral	$28.96M	-0.64	-87.18%	―	―	38.42%
CTXR	45 Neutral	$16.78M	-0.26	-54.40%	―	―	18.73%
SYBX	40 Underperform	$7.25M	-2.34	-27.54%	―	-100.00%	93.62%

Citius Pharmaceuticals Corporate Events

Citius Pharmaceuticals Posts First Revenue Amid Listing Risk

On February 9, 2026, Citius Pharmaceuticals received notice that its Nasdaq-listed common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance or face potential delisting, though trading under the CTXR symbol continues while the company evaluates remedies. Separately, on February 13, 2026, the company reported its first-ever revenue of $3.9 million from LYMPHIR sales following the drug’s December 2025 U.S. launch, alongside $20.9 million in equity financing, reduced R&D spending, and a narrower quarterly net loss, underscoring an early but pivotal commercial inflection amid ongoing Nasdaq listing risk and continued investment in its late-stage pipeline.

Citius Oncology’s LYMPHIR launch has seen early U.S. physician uptake via a nationwide distributor network, supported by an AI-enabled commercial platform targeting a concentrated prescriber base in this rare cancer market. Management is also pursuing international access through named patient programs in Europe and the Middle East and exploring broader clinical utility via investigator-initiated combination studies, moves that could expand LYMPHIR’s addressable market and reinforce Citius Oncology’s competitive position.

For the quarter ended December 31, 2025, Citius reported $7.7 million in cash and cash equivalents, with operations bolstered by capital raised at both the parent and oncology subsidiary levels. While general and administrative and stock-based compensation expenses increased, the company’s net loss narrowed year over year, reflecting the initial contribution from product revenue and tighter R&D spending as it engages with the FDA on next steps for Mino-Lok and Halo-Lido.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma

On December 1, 2025, Citius Oncology, Inc., a subsidiary of Citius Pharmaceuticals, announced the commercial launch of LYMPHIR™, a novel IL-2 receptor-directed fusion protein. This product, approved by the FDA, is designed for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. The launch marks a significant milestone for Citius Oncology as LYMPHIR is their first marketed product, potentially impacting the company’s market position and providing growth opportunities in the estimated $400 million U.S. market for this condition.

The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.